Genmab A/S (GMAB)
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
- Symbol
- GMAB
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- 52 week range
- 23.62 - 35.66
Valuation
- Share price
- $34.75 (close of 2026-09-23)
- P/E (TTM)
- 30.05x
- Price to book
- 4.74x
- Price to free cash flow
- 15.80x
Price performance
| Period | Change |
|---|---|
| 1 day | +0.17% |
| 5 days | +1.76% |
| 1 month | +3.89% |
| 3 months | +33.96% |
| 6 months | +35.32% |
| Year to date | +12.82% |
| 1 year | +20.95% |
| 3 years | -3.69% |
| 5 years | -22.57% |
| 10 years | +101.10% |
| All time | +821.75% |
Profitability and growth
- Return on equity
- 21.38%
- Return on invested capital
- 14.61%
- Return on assets
- 17.12%
- Gross margin
- 95.42%
- Net margin
- 36.44%
- EBITDA margin
- 31.14%
- Revenue growth
- 30.67%
- Net income growth
- 80.24%
- Free cash flow growth
- 8.13%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.33%
- Current ratio
- 5.03x
- Net debt to EBITDA
- -0.64x
Latest reported year
- Period end
- 2024-12-31
- Fiscal year
- 2024
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2024-12-31 | 95.42% | 36.44% | 21.38% | 14.61% |
| 2023-12-31 | 98.63% | 26.42% | 13.77% | 12.72% |
| 2022-12-31 | 81.55% | 37.59% | 0.00% | 5555.99% |
| 2021-12-31 | 84.76% | 35.13% | 0.00% | - |
| 2020-12-31 | 93.46% | 47.06% | 0.00% | - |
| 2019-12-31 | 93.63% | 40.37% | 15.42% | 18.22% |
| 2018-12-31 | 92.93% | 48.66% | 18.37% | 16.58% |
| 2017-12-31 | 93.78% | 46.68% | 17.60% | 27.29% |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-06 | Jun/2026 | - |
| 2026-05-07 | - | - |
| 2026-02-17 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-08 | - | - |
| 2025-02-12 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- genmab.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades